Polysomnographic and pharmacokinetic findings in levodopa‐induced augmentation of restless legs syndrome
Identifieur interne : 003271 ( Main/Exploration ); précédent : 003270; suivant : 003272Polysomnographic and pharmacokinetic findings in levodopa‐induced augmentation of restless legs syndrome
Auteurs : Roberto Vetrugno [Italie] ; Manuela Contin [Italie] ; Agostino Baruzzi [Italie] ; Federica Provini [Italie] ; Giuseppe Plazzi [Italie] ; Pasquale Montagna [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Levodopa, Levodopa (administration & dosage), Levodopa (adverse effects), Levodopa (pharmacokinetics), Metabolic Clearance Rate (physiology), Nervous system diseases, Pharmacokinetics, Polysomnography, Restless Legs Syndrome (blood), Restless Legs Syndrome (chemically induced), Restless Legs Syndrome (diagnosis), Restless Legs Syndrome (drug therapy), Restless legs syndrome, Spasm (blood), Spasm (chemically induced), Spasm (diagnosis), augmentation, levodopa, pharmacokinetic, polysomnography, restless legs syndrome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacokinetics : Antiparkinson Agents, Levodopa.
- blood : Restless Legs Syndrome, Spasm.
- chemically induced : Restless Legs Syndrome, Spasm.
- diagnosis : Restless Legs Syndrome, Spasm.
- drug therapy : Restless Legs Syndrome.
- physiology : Metabolic Clearance Rate.
- Aged, Disease Progression, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Polysomnography.
Abstract
Augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half‐life of the drug, is associated with dopaminergic treatment in restless legs syndrome (RLS) patients. The pathogenesis of augmentation is unclear. We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. This case is the first report in which RLS augmentation is shown to be characterized by motor hyperkinesias paralleling levodopa plasma pharmacokinetic profile. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20677
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002C10
- to stream Istex, to step Curation: 002C10
- to stream Istex, to step Checkpoint: 001D30
- to stream PubMed, to step Corpus: 002E62
- to stream PubMed, to step Curation: 002E62
- to stream PubMed, to step Checkpoint: 002B64
- to stream Ncbi, to step Merge: 001450
- to stream Ncbi, to step Curation: 001450
- to stream Ncbi, to step Checkpoint: 001450
- to stream Main, to step Merge: 004584
- to stream PascalFrancis, to step Corpus: 001C50
- to stream PascalFrancis, to step Curation: 001071
- to stream PascalFrancis, to step Checkpoint: 001961
- to stream Main, to step Merge: 004A56
- to stream Main, to step Curation: 003271
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Polysomnographic and pharmacokinetic findings in levodopa‐induced augmentation of restless legs syndrome</title><author><name sortKey="Vetrugno, Roberto" sort="Vetrugno, Roberto" uniqKey="Vetrugno R" first="Roberto" last="Vetrugno">Roberto Vetrugno</name></author><author><name sortKey="Contin, Manuela" sort="Contin, Manuela" uniqKey="Contin M" first="Manuela" last="Contin">Manuela Contin</name></author><author><name sortKey="Baruzzi, Agostino" sort="Baruzzi, Agostino" uniqKey="Baruzzi A" first="Agostino" last="Baruzzi">Agostino Baruzzi</name></author><author><name sortKey="Provini, Federica" sort="Provini, Federica" uniqKey="Provini F" first="Federica" last="Provini">Federica Provini</name></author><author><name sortKey="Plazzi, Giuseppe" sort="Plazzi, Giuseppe" uniqKey="Plazzi G" first="Giuseppe" last="Plazzi">Giuseppe Plazzi</name></author><author><name sortKey="Montagna, Pasquale" sort="Montagna, Pasquale" uniqKey="Montagna P" first="Pasquale" last="Montagna">Pasquale Montagna</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D3654B0B893B80B1548BDBAFB4A5ADE946F5272F</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20677</idno><idno type="url">https://api.istex.fr/document/D3654B0B893B80B1548BDBAFB4A5ADE946F5272F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002C10</idno><idno type="wicri:Area/Istex/Curation">002C10</idno><idno type="wicri:Area/Istex/Checkpoint">001D30</idno><idno type="wicri:doubleKey">0885-3185:2006:Vetrugno R:polysomnographic:and:pharmacokinetic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16200540</idno><idno type="wicri:Area/PubMed/Corpus">002E62</idno><idno type="wicri:Area/PubMed/Curation">002E62</idno><idno type="wicri:Area/PubMed/Checkpoint">002B64</idno><idno type="wicri:Area/Ncbi/Merge">001450</idno><idno type="wicri:Area/Ncbi/Curation">001450</idno><idno type="wicri:Area/Ncbi/Checkpoint">001450</idno><idno type="wicri:doubleKey">0885-3185:2006:Vetrugno R:polysomnographic:and:pharmacokinetic</idno><idno type="wicri:Area/Main/Merge">004584</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0171955</idno><idno type="wicri:Area/PascalFrancis/Corpus">001C50</idno><idno type="wicri:Area/PascalFrancis/Curation">001071</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001961</idno><idno type="wicri:doubleKey">0885-3185:2006:Vetrugno R:polysomnographic:and:pharmacokinetic</idno><idno type="wicri:Area/Main/Merge">004A56</idno><idno type="wicri:Area/Main/Curation">003271</idno><idno type="wicri:Area/Main/Exploration">003271</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Polysomnographic and pharmacokinetic findings in levodopa‐induced augmentation of restless legs syndrome</title><author><name sortKey="Vetrugno, Roberto" sort="Vetrugno, Roberto" uniqKey="Vetrugno R" first="Roberto" last="Vetrugno">Roberto Vetrugno</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Contin, Manuela" sort="Contin, Manuela" uniqKey="Contin M" first="Manuela" last="Contin">Manuela Contin</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Baruzzi, Agostino" sort="Baruzzi, Agostino" uniqKey="Baruzzi A" first="Agostino" last="Baruzzi">Agostino Baruzzi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Provini, Federica" sort="Provini, Federica" uniqKey="Provini F" first="Federica" last="Provini">Federica Provini</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Plazzi, Giuseppe" sort="Plazzi, Giuseppe" uniqKey="Plazzi G" first="Giuseppe" last="Plazzi">Giuseppe Plazzi</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author><author><name sortKey="Montagna, Pasquale" sort="Montagna, Pasquale" uniqKey="Montagna P" first="Pasquale" last="Montagna">Pasquale Montagna</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Sciences, University of Bologna, Bologna</wicri:regionArea><wicri:noRegion>Bologna</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-02">2006-02</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="254">254</biblScope><biblScope unit="page" to="258">258</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D3654B0B893B80B1548BDBAFB4A5ADE946F5272F</idno><idno type="DOI">10.1002/mds.20677</idno><idno type="ArticleID">MDS20677</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Disease Progression</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Levodopa</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Metabolic Clearance Rate (physiology)</term><term>Nervous system diseases</term><term>Pharmacokinetics</term><term>Polysomnography</term><term>Restless Legs Syndrome (blood)</term><term>Restless Legs Syndrome (chemically induced)</term><term>Restless Legs Syndrome (diagnosis)</term><term>Restless Legs Syndrome (drug therapy)</term><term>Restless legs syndrome</term><term>Spasm (blood)</term><term>Spasm (chemically induced)</term><term>Spasm (diagnosis)</term><term>augmentation</term><term>levodopa</term><term>pharmacokinetic</term><term>polysomnography</term><term>restless legs syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Restless Legs Syndrome</term><term>Spasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Metabolic Clearance Rate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease Progression</term><term>Dose-Response Relationship, Drug</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Polysomnography</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Impatience membre inférieur syndrome</term><term>Lévodopa</term><term>Pharmacocinétique</term><term>Polysomnographie</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half‐life of the drug, is associated with dopaminergic treatment in restless legs syndrome (RLS) patients. The pathogenesis of augmentation is unclear. We describe a patient with idiopathic RLS who developed augmentation after 8 months of levodopa treatment. Videopolysomnographic and pharmacokinetic studies with monitoring of plasma levodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. Symptoms and signs of augmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. This case is the first report in which RLS augmentation is shown to be characterized by motor hyperkinesias paralleling levodopa plasma pharmacokinetic profile. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Vetrugno, Roberto" sort="Vetrugno, Roberto" uniqKey="Vetrugno R" first="Roberto" last="Vetrugno">Roberto Vetrugno</name></noRegion><name sortKey="Baruzzi, Agostino" sort="Baruzzi, Agostino" uniqKey="Baruzzi A" first="Agostino" last="Baruzzi">Agostino Baruzzi</name><name sortKey="Contin, Manuela" sort="Contin, Manuela" uniqKey="Contin M" first="Manuela" last="Contin">Manuela Contin</name><name sortKey="Montagna, Pasquale" sort="Montagna, Pasquale" uniqKey="Montagna P" first="Pasquale" last="Montagna">Pasquale Montagna</name><name sortKey="Plazzi, Giuseppe" sort="Plazzi, Giuseppe" uniqKey="Plazzi G" first="Giuseppe" last="Plazzi">Giuseppe Plazzi</name><name sortKey="Provini, Federica" sort="Provini, Federica" uniqKey="Provini F" first="Federica" last="Provini">Federica Provini</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003271 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003271 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D3654B0B893B80B1548BDBAFB4A5ADE946F5272F
|texte= Polysomnographic and pharmacokinetic findings in levodopa‐induced augmentation of restless legs syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |